SEGLUROMET

Peak

ertugliflozin and metformin hydrochloride

Merck & Co.
NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100

Loss of Exclusivity

LOE Date
Oct 21, 2030
56 months away
Patent Expiry
Oct 21, 2030

Patent Records (3)

Patent #ExpiryTypeUse Code
8080580
Jul 13, 2030
SubstanceProduct
U-2214
9308204
Oct 21, 2030
Product
—
9439902
Oct 21, 2030
U-2214
Company
M&
Merck & Co.
RAHWAY, NJ
636 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers